<DOC>
	<DOC>NCT01103180</DOC>
	<brief_summary>The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.</brief_summary>
	<brief_title>Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Personality Disorders</mesh_term>
	<mesh_term>Borderline Personality Disorder</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Diagnosis of Borderline Personality Disorder Current Major Depression Past 2 months SSRI use Past 6 months nonSSRI antidepressant use Past 2 months initiation of psychotherapy Lifetime bipolar disorder, organic disorder, psychotic disorder Current alcohol or drug dependence Current severe suicidal / homicidal ideation necessitating immediate medical intervention Currently pregnancy or nursing Unable or unwilling to cooperate with study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Selective Serotonin Reuptake Inhibitor</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Borderline Personality Disorder</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Self-harm</keyword>
</DOC>